Strategic Acquisitions and Divestitures
Announced the acquisition of Evergreen Theragnostics and Life Molecular Imaging, aimed at enhancing radiopharmaceutical capabilities and growth. Also announced the divestment of the SPECT business to SHINE Technologies.
Strong Product Performance
PYLARIFY sales for the first quarter were $258 million, despite a low-single-digit decline in net price. DEFINITY achieved approximately $79 million in sales, even with the return of competitive supply to the U.S. market.
Positive Pipeline Developments
MK-6240, a next-generation tau imaging agent, met its primary endpoints in two pivotal studies. The company plans to submit a new drug application to the FDA in the third quarter of 2025.
Financial Stability
Operating cash flow for the first quarter was $107.6 million, with a strong liquidity position of $938.5 million in cash and cash equivalents.